View all press releases

Tetra Bio-Pharma Announces Outcome of its Meeting with its Scientific and Clinical Advisory Board

11/02/2016

Ottawa, Ontario – (Marketwired – November 2, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company”) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP”), is pleased to announce that it held its Scientific and Clinical Advisory Board (“CAB”) meeting on October 29th. The CAB reviewed the development program of PPP’s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe.

Categories: Press Releases
View all press releases